ADJUVANT AUTOLOGOUS INTRAVESICAL MACROPHAGE CELL THERAPY VS. BCG FOR NON-MUSCLE INVASIVE BLADDER CANCER: A PHASE II, MULTICENTER, RANDOMIZED TRIAL

被引：0

作者：

Burger, M. ^{[1
]}

Thiounn, N. ^{[2
]}

Denzinger, N. ^{[1
]}

Malavaud, B. ^{[3
]}

Wirth, M. ^{[4
]}

Thueroff, J. W. ^{[5
]}

Romics, I. ^{[6
]}

Colombel, M. ^{[7
]}

Solsona, E. ^{[8
]}

Tombal, B. ^{[9
]}

Sherman, J. ^{[10
]}

机构：

[1] Univ Regensburg, Dept Urol, Regensburg, Germany

[2] Univ Paris 05, Dept Urol, Paris, France

[3] Paris St Joseph Hosp Trust, Dept Urol, Paris, France

[4] Univ Dresden, Dept Urol, Dresden, Germany

[5] Johannes Gutenberg Univ Mainz, Dept Urol, Mainz, Germany

[6] Semmelweis Univ, Dept Urol, H-1085 Budapest, Hungary

[7] Hop Edouard Herriot, Dept Urol, Lyon, France

[8] Inst Valenciano Oncol, Dept Urol, Valencia, Spain

[9] Clin Univ St Luc, Dept Urol, B-1200 Brussels, Belgium

[10] IDM Pharma, Dept Med, Irvine, CA USA

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2009年 / 8卷 / 04期

关键词：

D O I：

10.1016/S1569-9056(09)60652-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：285 / 285

页数：1

共 50 条

[21] Adjuvant cancer peptide vaccine treatment with intravesical BCG therapy for non-muscle-invasive bladder cancer
Obara, Wataru
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[22] The role of molecular genetic alterations in sensitivity of the adjuvant intravesical therapy for non-muscle invasive bladder cancer
Mikhaylenko, D. S.
Sergienko, S. A.
Zaborsky, I. N.
Safiullin, K. N.
Serebryany, S. A.
Safronova, N. Yu.
Nemtsova, M. V.
Kaprin, A. D.
Alekseev, B. Ya.
ONKOUROLOGIYA, 2018, 14 (04): : 124 - 138
[23] Predictors of response to BCG therapy in non-muscle invasive bladder cancer
Radovanovic, Milan
Petrovic, Milos
Santric, Veljko
Zubelic, Aleksa
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2022, 150 (1-2) : 113 - 116
[24] A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder
DeCastro, G. J.
Stein, M.
Abate-Shen, C.
Miles, C.
Gray, J.
Joffe, B.
Anderson, C.
Lenis, A.
McKiernan, J. M. M.
ANNALS OF ONCOLOGY, 2024, 35 : S1143 - S1143
[25] Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non-muscle invasive bladder cancer?
Di Stasi, Savino Mauro
Riedl, Claus
Verri, Cristian
Celestino, Francesco
De Carlo, Francesco
Giannantoni, Antonella
Zampa, Germano
Valenti, Marco
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC)
Guleria, K.
Sood, R.
Goel, H.
Sharma, U.
Singla, A.
ANNALS OF ONCOLOGY, 2022, 33 : S1486 - S1487
[27] Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Vivek Sharma
Avinash P. S. Thakur
Vasantharaja Ramasamy
Pushpendra Kumar Shukla
Fanindra Singh Solanki
Arpan Choudhary
Prashant Patel
African Journal of Urology, 2020, 26
[28] Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
Sharma, Vivek
Thakur, Avinash P. S.
Ramasamy, Vasantharaja
Shukla, Pushpendra Kumar
Solanki, Fanindra Singh
Choudhary, Arpan
Patel, Prashant
AFRICAN JOURNAL OF UROLOGY, 2020, 26 (01)
[29] A RANDOMIZED STUDY TO COMPARE OUTCOMES OF INTRAVESICAL CHEMOHYPERTHERMIA WITH MITOMYCIN C VS INTRAVESICAL BCG FOR INTERMEDIATE AND HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Guleria, Karandeep
Sood, Rajeev
Goel, Hemant
Sharma, Umesh
Singla, Anurag
JOURNAL OF UROLOGY, 2022, 207 (05): : E488 - E488
[30] Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG und mitomycin C
Gakis, Georgios
AKTUELLE UROLOGIE, 2022, 53 (02) : 148 - 152

← 1 2 3 4 5 →